The receptor RAGE: Bridging inflammation and cancer

Cell Communication and Signaling

Volumn 7, Issue , 2009, Pages

  Riehl, Astrid ^a   Németh, Julia ^a   Angel, Peter ^a   Hess, Jochen ^a  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955769241     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-7-12     Document Type: Review

References (56)

1. Inflammation and cancer. LM Coussens, Z Werb, Nature 2002 420 860 867 10.1038/nature01322 12490959
2. Inflammation and cancer: back to Virchow? F Balkwill, A Mantovani, Lancet 2001 357 539 545 10.1016/S0140-6736(00)04046-0 11229684
3. Paradoxical roles of the immune system during cancer development. KE de Visser, A Eichten, LM Coussens, Nat Rev Cancer 2006 6 24 37 10.1038/nrc1782 16397525
4. Cancer-related inflammation. A Mantovani, P Allavena, A Sica, F Balkwill, Nature 2008 454 436 444 10.1038/nature07205 18650914
5. Cytokines as a key component of cancer-related inflammation. G Germano, P Allavena, A Mantovani, Cytokine 2008 43 374 379 10.1016/j.cyto.2008.07.014 18701317
6. A cytokine-mediated link between innate immunity, inflammation, and cancer. WW Lin, M Karin, J Clin Invest 2007 117 1175 1183 10.1172/JCI31537 17476347
7. NF-kappaB: linking inflammation and immunity to cancer development and progression. M Karin, FR Greten, Nat Rev Immunol 2005 5 749 759 10.1038/nri1703 16175180
8. Pathways connecting inflammation and cancer. P Allavena, C Garlanda, MG Borrello, A Sica, A Mantovani, Curr Opin Genet Dev 2008 18 3 10 10.1016/j.gde.2008.01.003 18325755
9. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. AM Schmidt, SD Yan, SF Yan, DM Stern, J Clin Invest 2001 108 949 955 11581294
10. Understanding RAGE, the receptor for advanced glycation end products. A Bierhaus, PM Humpert, M Morcos, T Wendt, T Chavakis, B Arnold, DM Stern, PP Nawroth, J Mol Med 2005 83 876 886 10.1007/s00109-005-0688-7 16133426
11. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. K Ishihara, K Tsutsumi, S Kawane, M Nakajima, T Kasaoka, FEBS Letters 2003 550 107 113 10.1016/S0014-5793(03)00846-9 12935895
12. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. BI Hudson, AZ Kalea, MD Arriero, E Harja, E Boulanger, V D'Agati, AM Schmidt, J Biol Chem 2008 283 34457 34468 10.1074/jbc.M801465200 18922799
13. RAGE: A Single Receptor for Several Ligands and Different Cellular Responses: The Case of Certain S100 Proteins. R Donato, Curr Mol Med 2007 7 711 724 18331229 10.2174/156652407783220688
14. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. R Clynes, B Moser, SF Yan, R Ramasamy, K Herold, AM Schmidt, Curr Mol Med 2007 7 743 751 10.2174/156652407783220714 18331232
15. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. K Herold, B Moser, Y Chen, S Zeng, SF Yan, R Ramasamy, J Emond, R Clynes, AM Schmidt, J Leukoc Biol 2007 82 204 212 10.1189/jlb.1206751 17513693
16. Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. C Bopp, A Bierhaus, S Hofer, A Bouchon, P Nawroth, E Martin, M Weigand, Crit Care 2008 12 201 10.1186/cc6164 18226173
17. Advanced glycation end product receptor-mediated cellular dysfunction. A Bierhaus, PM Humpert, DM Stern, B Arnold, PP Nawroth, Ann N Y Acad Sci 2005 1043 676 680 10.1196/annals.1333.077 16037292
18. RAGE in inflammation: a new therapeutic target? A Bierhaus, DM Stern, PP Nawroth, Curr Opin Investig Drugs 2006 7 985 991 17117586
19. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). KS Collison, RS Parhar, SS Saleh, BF Meyer, AA Kwaasi, MM Hammami, AM Schmidt, DM Stern, FA Al-Mohanna, J Leukoc Biol 2002 71 433 444 11867681
20. RAGE signaling sustains inflammation and promotes tumor development. C Gebhardt, A Riehl, M Durchdewald, J Nemeth, G Furstenberger, K Muller-Decker, A Enk, B Arnold, A Bierhaus, PP Nawroth, J Hess, P Angel, J Exp Med 2008 205 275 285 10.1084/jem.20070679 18208974
21. RAGE ligation affects T cell activation and controls T cell differentiation. Y Chen, EM Akirav, W Chen, O Henegariu, B Moser, D Desai, JM Shen, JC Webster, RC Andrews, AM Mjalli, R Rothlein, AM Schmidt, R Clynes, KC Herold, J Immunol 2008 181 4272 4278 18768885
22. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. T Chavakis, A Bierhaus, N Al-Fakhri, D Schneider, S Witte, T Linn, M Nagashima, J Morser, B Arnold, KT Preissner, PP Nawroth, J Exp Med 2003 198 1507 1515 10.1084/jem.20030800 14623906
23. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. VV Orlova, EY Choi, C Xie, E Chavakis, A Bierhaus, E Ihanus, CM Ballantyne, CG Gahmberg, ME Bianchi, PP Nawroth, T Chavakis, Embo J 2007 26 1129 1139 10.1038/sj.emboj.7601552 17268551
24. S100A8 and S100A9 in inflammation and cancer. C Gebhardt, J Nemeth, P Angel, J Hess, Biochem Pharmacol 2006 72 1622 1631 10.1016/j.bcp.2006.05.017 16846592
25. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. D Foell, H Wittkowski, T Vogl, J Roth, J Leukoc Biol 2007 81 28 37 10.1189/jlb.0306170 16943388
26. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. ME Bianchi, AA Manfredi, Immunol Rev 2007 220 35 46 10.1111/j.1600-065X.2007.00574.x 17979838
27. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Li, AM Schmidt, J Biol Chem 1997 272 16498 16506 10.1074/jbc.272.26.16498 9195959
28. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. J Brett, AM Schmidt, SD Yan, YS Zou, E Weidman, D Pinsky, R Nowygrod, M Neeper, C Przysiecki, A Shaw, et al. Am J Pathol 1993 143 1699 1712 8256857
29. Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. N Demling, C Ehrhardt, M Kasper, M Laue, L Knels, EP Rieber, Cell Tissue Res 2006 323 475 488 10.1007/s00441-005-0069-0 16315007
30. Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray. TS Tanaka, SA Jaradat, MK Lim, GJ Kargul, X Wang, MJ Grahovac, S Pantano, Y Sano, Y Piao, R Nagaraja, H Doi, WH Wood 3rd, KG Becker, MS Ko, Proc Natl Acad Sci USA 2000 97 9127 9132 10.1073/pnas.97.16.9127 10922068
31. The biology of the receptor for advanced glycation end products and its ligands. AM Schmidt, SD Yan, SF Yan, DM Stern, Biochim Biophys Acta 2000 1498 99 111 10.1016/S0167-4889(00)00087-2 11108954
32. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. A Bierhaus, S Schiekofer, M Schwaninger, M Andrassy, PM Humpert, J Chen, M Hong, T Luther, T Henle, I Kloting, M Morcos, M Hofmann, H Tritschler, B Weigle, M Kasper, M Smith, G Perry, AM Schmidt, DM Stern, HU Häring, E Schleicher, PP Nawroth, Diabetes 2001 50 2792 2808 10.2337/diabetes.50.12.2792 11723063
33. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. LG Bucciarelli, T Wendt, L Rong, E Lalla, MA Hofmann, MT Goova, A Taguchi, SF Yan, SD Yan, DM Stern, AM Schmidt, Cell Mol Life Sci 2002 59 1117 1128 10.1007/s00018-002-8491-x 12222959
34. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. B Liliensiek, MA Weigand, A Bierhaus, W Nicklas, M Kasper, S Hofer, J Plachky, HJ Grone, FC Kurschus, AM Schmidt, SD Yan, E Martin, E Schleicher, DM Stern, GG Hämmerling, PP Nawroth, B Arnold, J Clin Invest 2004 113 1641 1650 15173891
35. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. EC Lutterloh, SM Opal, DD Pittman, JC Keith Jr, XY Tan, BM Clancy, H Palmer, K Milarski, Y Sun, JE Palardy, NA Parejo, N Kessimian, Crit Care 2007 11 122 10.1186/cc6184 18042296
36. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. SS Yan, ZY Wu, HP Zhang, G Furtado, X Chen, SF Yan, AM Schmidt, C Brown, A Stern, J LaFaille, L Chess, DM Stern, H Jiang, Nat Med 2003 9 287 293 10.1038/nm831 12598893
37. RAGE and RAGE ligands in cancer. CD Logsdon, MK Fuentes, EH Huang, T Arumugam, Curr Mol Med 2007 7 777 789 10.2174/156652407783220697 18331236
38. AGE-RAGE system and carcinogenesis. R Abe, S Yamagishi, Curr Pharm Des 2008 14 940 945 10.2174/138161208784139765 18473843
39. Masquerader: high mobility group box-1 and cancer. JE Ellerman, CK Brown, M de Vera, HJ Zeh, T Billiar, A Rubartelli, MT Lotze, Clin Cancer Res 2007 13 2836 2848 10.1158/1078-0432.CCR-06-1953 17504981
40. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. A Taguchi, DC Blood, G del Toro, A Canet, DC Lee, W Qu, N Tanji, Y Lu, E Lalla, C Fu, MA Hofmann, T Kislinger, M Ingram, A Lu, H Tanaka, O Hori, S Ogawa, DM Stern, AM Schmidt, Nature 2000 405 354 360 10.1038/35012626 10830965
41. Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. P Schraml, I Bendik, CU Ludwig, Cancer Res 1997 57 3669 3671 9288769
42. Usefulness of CDK5RAP3, CCNB2, and RAGE genes for the diagnosis of lung adenocarcinoma. D Stav, I Bar, J Sandbank, Int J Biol Markers 2007 22 108 113 17549666
43. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. B Bartling, HS Hofmann, B Weigle, RE Silber, A Simm, Carcinogenesis 2005 26 293 301 10.1093/carcin/bgh333 15539404
44. Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. B Bartling, N Demling, RE Silber, A Simm, Am J Respir Cell Mol Biol 2006 34 83 91 10.1165/rcmb.2005-0194OC 16166741
45. Endogenous secretory receptor for advanced glycation end products in non-small cell lung carcinoma. S Kobayashi, H Kubo, T Suzuki, K Ishizawa, M Yamada, M He, Y Yamamoto, H Yamamoto, H Sasano, H Sasaki, S Suzuki, Am J Respir Crit Care Med 2007 175 184 189 10.1164/rccm.200602-212OC 17023736
46. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. F Riuzzi, G Sorci, R Donato, J Biol Chem 2006 281 8242 8253 10.1074/jbc.M509436200 16407300
47. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. F Riuzzi, G Sorci, R Donato, Am J Pathol 2007 171 947 961 10.2353/ajpath.2007.070049 17640970
48. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. O Turovskaya, D Foell, P Sinha, T Vogl, R Newlin, J Nayak, M Nguyen, A Olsson, PP Nawroth, A Bierhaus, N Varki, M Kronenberg, HH Freeze, G Srikrishna, Carcinogenesis 2008 29 2035 2043 10.1093/carcin/bgn188 18689872
49. Malignant progression of papillomas induced by the initiation-promotion protocol in NMRI mouse skin. G Furstenberger, A Kopp-Schneider, Carcinogenesis 1995 16 61 69 10.1093/carcin/16.1.61 7834806
50. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. S Ghavami, I Rashedi, BM Dattilo, M Eshraghi, WJ Chazin, M Hashemi, S Wesselborg, C Kerkhoff, M Los, J Leukoc Biol 2008 83 1484 1492 10.1189/jlb.0607397 18339893
51. N-Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. G Srikrishna, HJ Huttunen, L Johansson, B Weigle, Y Yamaguchi, H Rauvala, HH Freeze, J Neurochem 2002 80 998 1008 10.1046/j.0022-3042.2002.00796.x 11953450
52. Carboxylated glycans mediate colitis through activation of NF-kappa B. G Srikrishna, O Turovskaya, R Shaikh, R Newlin, D Foell, S Murch, M Kronenberg, HH Freeze, J Immunol 2005 175 5412 5422 16210648
53. Cancer immunology. Cancer's bulwark against immune attack: MDS cells. J Marx, Science 2008 319 154 156 10.1126/science.319.5860.154 18187637
54. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. P Cheng, CA Corzo, N Luetteke, B Yu, S Nagaraj, MM Bui, M Ortiz, W Nacken, C Sorg, T Vogl, J Roth, DI Gabrilovich, J Exp Med 2008 205 2235 2249 10.1084/jem.20080132 18809714
55. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. P Sinha, C Okoro, D Foell, HH Freeze, S Ostrand-Rosenberg, G Srikrishna, J Immunol 2008 181 4666 4675 18802069
56. RAGE on the Toll Road? L Lin, Cell Mol Immunol 2006 3 351 358 17092432